Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Patrick Burnett Sells 6,287 Shares

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Patrick Burnett sold 6,287 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $25.18, for a total transaction of $158,306.66. Following the completion of the transaction, the insider owned 121,150 shares of the company’s stock, valued at $3,050,557. This represents a 4.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Patrick Burnett also recently made the following trade(s):

• On Wednesday, February 4th, Patrick Burnett sold 9,794 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $25.81, for a total transaction of $252,783.14.
• On Monday, February 2nd, Patrick Burnett sold 3,675 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $25.50, for a total transaction of $93,712.50.
• On Monday, January 5th, Patrick Burnett sold 2,490 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $28.98, for a total transaction of $72,160.20.
• On Wednesday, December 31st, Patrick Burnett sold 1,697 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $29.20, for a total value of $49,552.40.
• On Monday, December 15th, Patrick Burnett sold 11,500 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $28.94, for a total transaction of $332,810.00.

Arcutis Biotherapeutics Stock Performance

Shares of ARQT stock opened at $23.60 on Wednesday. Arcutis Biotherapeutics, Inc. has a 52 week low of $11.86 and a 52 week high of $31.77. The company’s fifty day simple moving average is $27.02 and its 200-day simple moving average is $24.03. The company has a current ratio of 3.17, a quick ratio of 2.99 and a debt-to-equity ratio of 0.57. The company has a market cap of $2.93 billion, a PE ratio of -168.56 and a beta of 1.66.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.03 by $0.10. Arcutis Biotherapeutics had a negative return on equity of 10.26% and a negative net margin of 4.29%.The firm had revenue of $129.50 million for the quarter, compared to analyst estimates of $110.79 million. As a group, equities research analysts anticipate that Arcutis Biotherapeutics, Inc. will post -1.33 EPS for the current year.

Key Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Pipeline update — Arcutis enrolled the first participant in a Phase 1a/1b study of ARQ‑234 (a CD200R agonist) to assess safety/tolerability in healthy volunteers and adults with moderate‑to‑severe atopic dermatitis. This is a clear development catalyst supporting longer‑term growth potential. Read More.
• Neutral Sentiment: Broker update — Mizuho trimmed its price target (reported moves show PT cut from $37 to $35) but retained an Outperform stance; that lowers near‑term upside while keeping analyst conviction intact. Read More.
• Neutral Sentiment: Fund filings — Baron Health Care Fund published Q4 activity (no clear large position change in ARQT reported), so fund flows aren’t a decisive driver based on available filings. Read More.
• Neutral Sentiment: Short‑interest reporting in the feeds is inconsistent/erroneous (reports show 0 shares / NaN changes) and provides no reliable signal; treat those numbers as unreliable until clarified by exchange data.
• Negative Sentiment: Clustered insider selling — Multiple insiders sold shares between Feb 27–Mar 2 (notable filings: Todd Watanabe ~37,349 shares; Masaru Matsuda 8,733 shares plus earlier sales; CFO Latha Vairavan; Patrick Burnett). Aggregated insider dispositions total tens of thousands of shares and are likely weighing on sentiment because clustered sales often trigger investor concern. Representative filings: Watanabe Form 4 Read More., Matsuda Form 4 Read More., MarketBeat roundup Read More.
• Negative Sentiment: Analyst downgrade / negative note — Coverage cited in the newsfeed reports a downgrade and a pessimistic near‑term forecast that corresponded with a sharp intraday drop; that broker action appears to have amplified selling pressure. Read More.

Analysts Set New Price Targets

ARQT has been the subject of a number of analyst reports. Mizuho decreased their price objective on shares of Arcutis Biotherapeutics from $37.00 to $35.00 and set an “outperform” rating for the company in a research report on Monday. TD Cowen increased their price target on Arcutis Biotherapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Needham & Company LLC lifted their price objective on Arcutis Biotherapeutics from $31.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Guggenheim raised their price target on shares of Arcutis Biotherapeutics from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Finally, Zacks Research downgraded shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.86.

Institutional Trading of Arcutis Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in ARQT. Sit Investment Associates Inc. bought a new stake in shares of Arcutis Biotherapeutics during the 4th quarter valued at about $376,000. Invesco Ltd. grew its holdings in shares of Arcutis Biotherapeutics by 59.3% during the fourth quarter. Invesco Ltd. now owns 307,382 shares of the company’s stock valued at $8,926,000 after purchasing an additional 114,430 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in shares of Arcutis Biotherapeutics in the 4th quarter worth approximately $255,000. Mackenzie Financial Corp acquired a new position in Arcutis Biotherapeutics during the 4th quarter valued at approximately $1,374,000. Finally, NewEdge Advisors LLC grew its stake in Arcutis Biotherapeutics by 209.0% during the 4th quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock worth $45,000 after buying an additional 1,045 shares during the last quarter.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.